ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tislelizumab

Also written as “Tislelizumab”, “BGB-A317” and “Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Carcinoma, Hepatocellular · Stomach Neoplasms · Hodgkin Disease, led by 21 companies.

Drug pageTislelizumab: every studyMany companies study it; this page follows only the 74 they lead. All 434 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Nov 27, 201774 company-led studies, 20 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicines539 open or runningphase 3since Nov 27, 2017Mar 26, 2015Nov 2026phase 2 · NCT03736889
RemeGenits history only22 open or runningphase 3since Apr 17, 2025Apr 17, 2025May 15, 2028phase 3 · NCT06944496
Antengeneits history only10 open or runningphase 2since May 25, 2020May 25, 2020none ahead
Beijing Aosaikang Pharmaceuticalits history only11 open or runningphase 2since Nov 21, 2022Nov 21, 2022none ahead
Beijing Biostar Pharmaceuticalsits history only11 open or runningphase 2since Sep 18, 2026Sep 18, 2026Sep 20, 2028phase 2 · NCT07842276
BriaCell Therapeuticsits history only11 open or runningphase 2since Jun 11, 2024Jun 11, 2024none ahead
Bristol-Myers Squibbits history only10 open or runningphase 3since Nov 9, 2018Nov 9, 2018none ahead
Changchun GeneScience Pharmaceuticalits history only10 open or runningphase 1since Jun 16, 2022Jun 16, 2022none ahead
HUTCHMEDits history only10 open or runningphase 2since Sep 23, 2020Sep 23, 2020none ahead
Immix Biopharmaits history only11 open or runningphase 2since Jan 4, 2023Jan 4, 2023none ahead

Also a collaborator on its studies: Myriad Genetic Laboratories.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of BeOne Medicines only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 38 earlier studies, Mar 26, 2015 to Jul 3, 2021.

  1. Jun 9, 2017Named tislelizumabINNProposed as its International Nonproprietary Name in WHO's List 117
  2. Oct 20, 2021Phase 2 study in Colorectal NeoplasmsNCT05116085 · 33 enrolled · China
  3. Feb 10, 2022Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05267054 · 53 enrolled · China
  4. Jul 14, 2022Phase 2 study in Esophageal Squamous Cell CarcinomaNCT05461794 · 96 enrolled · China
  5. Aug 8, 2022Phase 1 study in Solid TumorNCT05494762 · 55 enrolled · United States, Australia
  6. Sep 29, 2022Phase 3 study in Carcinoma, HepatocellularNCT05564338
  7. Oct 10, 20222 phase 2 studiesNCT05577702, NCT05609370
  8. Nov 23, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05635708 · 418 enrolled · United States, Australia, Brazil and more
  9. Dec 1, 2022Phase 1 study in Solid TumorsNCT05644626
  10. Dec 15, 2022Phase 2 study in Carcinoma, Transitional CellNCT05661955 · 113 enrolled · China
  11. Jul 31, 2023Phase 1 study in Advanced Solid TumorNCT05981703 · 337 planned · United States, Australia, China and more
  12. Oct 16, 2023Phase 1 study in Carcinoma, Non-Small-Cell LungNCT06091943 · 62 enrolled · China, Georgia, Moldova
  13. Jun 20, 2025Phase 3 study in Metastatic Gastric AdenocarcinomaNCT07043400 · 351 planned · United States, Argentina, Austria and more
  14. Apr 21, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaNCT07554521 · 30 planned · United States
  15. Jul 22, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaNCT07733180 · 30 planned · Japan

Ahead

  1. Nov 2026Primary completion: phase 2 study in MSI-H/dMMR Solid TumorsNCT03736889
  2. Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Transitional CellNCT03967977
  3. Oct 30, 2027Primary completion: phase 3 study in Metastatic Gastric AdenocarcinomaNCT07043400
  4. Feb 28, 2028Primary completion: phase 2 study in Esophageal Squamous Cell CarcinomaNCT07733180

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 53 BeOne Medicines leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07733180Esophageal Squamous Cell Carcinoma · Japan2RecruitingFeb 28, 202830
NCT07554521Esophageal Squamous Cell Carcinoma · United States2RecruitingDec 31, 203130
NCT07043400Metastatic Gastric Adenocarcinoma · United States, Argentina, Austria and more3RecruitingOct 30, 2027351
NCT06091943Carcinoma, Non-Small-Cell Lung · China, Georgia, Moldova1CompletedJul 31, 202562
NCT05981703Advanced Solid Tumor · United States, Australia, China and more1RecruitingFeb 28, 2029337
NCT05661955Carcinoma, Transitional Cell · China2Active, not recruitingMay 27, 2025113
NCT05644626Solid Tumors1WithdrawnMar 20250
NCT05635708Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more2CompletedDec 19, 2025418
NCT05609370Colorectal Neoplasms · United States, Australia, China and more2Active, not recruitingMay 23, 2025113
NCT05577702Carcinoma, Non-Small-Cell Lung · China2CompletedDec 13, 2024121
NCT05564338Carcinoma, Hepatocellular3WithdrawnApr 30, 20270
NCT05494762Solid Tumor · United States, Australia1TerminatedFeb 24, 202555
NCT05461794Esophageal Squamous Cell Carcinoma · China2TerminatedFeb 26, 202496
NCT05267054Lymphoma, Large B-Cell, Diffuse · China2CompletedAug 30, 202453
NCT05116085Colorectal Neoplasms · China2CompletedSep 26, 202333
NCT05014828Advanced Solid Tumor · China2CompletedOct 20, 202358
NCT04974047Resectable Esophageal Squamous Cell Carcinoma · China2CompletedApr 17, 202370
NCT04948697Advanced Hepatocellular Carcinoma · China, Taiwan2CompletedFeb 1, 202494
NCT04921358Carcinoma, Non-Small-Cell Lung · Australia, China3TerminatedDec 20, 2023377
NCT04746924Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3TerminatedMay 30, 2025669
NCT04716634Advanced Solid Tumors · China, Korea, Republic of2CompletedFeb 22, 202484
NCT04693234Uterine Cervical Neoplasms · Bulgaria, China, Korea, Republic of and more2CompletedJun 16, 2022178
NCT04649385Advanced Solid Tumor · United States, Australia, China and more1CompletedOct 17, 2025157
NCT04866017Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more3TerminatedOct 17, 202363
NCT04486391Classical Hodgkin Lymphoma · China3TerminatedOct 13, 20253
NCT04401800Carcinoma, Hepatocellular · China2CompletedDec 1, 202264
NCT04379635Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingAug 21, 2023453
NCT04318080Classical Hodgkin Lymphoma · United States, Australia2CompletedDec 12, 202246
NCT04276493Breast Neoplasms · China, South Korea, Taiwan2CompletedDec 7, 202371
NCT04164199Advanced Malignancies · United States, Australia, China and more3CompletedMay 23, 2026404
NCT04068519Advanced Solid Tumors · China2CompletedDec 1, 2018300
NCT04005716Small Cell Lung Carcinoma · China3CompletedApr 19, 2023457
NCT04004221Locally Advanced or Metastatic Urothelial Bladder Cancer · China, Korea, Republic of2CompletedSep 16, 2019113
NCT03967977Carcinoma, Transitional Cell · China, Taiwan3Active, not recruitingJun 30, 2027420
NCT03957590Esophageal Squamous Cell Carcinoma · China3CompletedJan 8, 2025370
NCT03924986Recurrence · China, Taiwan, Thailand3CompletedMar 26, 2021263
NCT03783442Esophageal Squamous Cell Carcinoma · United States, Australia, Belgium and more3CompletedFeb 28, 2022649
NCT03777657Gastric, or Gastroesophageal Junction Adenocarcinoma · United States, China, France and more3CompletedFeb 28, 2023997
NCT03736889MSI-H/dMMR Solid Tumors · China2RecruitingNov 2026200
NCT03744468Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in · United States, Australia, France and more2CompletedFeb 6, 2025147
NCT03666143Advanced Solid Tumors · Australia, China1CompletedJan 5, 2023216
NCT03663205Carcinoma, Non-Small-Cell Lung · China3CompletedJan 23, 2020334
NCT03594747Carcinoma, Non-Small-Cell Lung · China3CompletedSep 30, 2020360
NCT03493451Lymphoma, T-Cell, Peripheral · Canada, China, France and more2CompletedApr 21, 202177
NCT03432598Lung Neoplasms · China2CompletedFeb 25, 201954
NCT03430843Esophageal Squamous Cell Carcinoma · United States, Belgium, China and more3CompletedDec 1, 2020512
NCT03419897Carcinoma, Hepatocellular · China, France, Germany and more2CompletedJun 30, 2021249
NCT03412773Carcinoma, Hepatocellular · United States, China, Czechia and more3CompletedJul 11, 2022684
NCT03358875Carcinoma, Non-Small-Cell Lung · Brazil, Bulgaria, China and more3CompletedJul 15, 2021805
NCT03209973Classical Hodgkin Lymphoma · China2CompletedNov 2, 202070
NCT02795182Lymphoma · Australia, China1CompletedDec 18, 202075
NCT02660034Solid Tumors · United States, Australia, France and more1CompletedSep 9, 2020229
NCT02407990Advanced Cancer · United States, Australia, Korea, Republic of and more1CompletedAug 12, 2020451

How it is read

Names in the registry

  • “Tislelizumab”, 57 entries
  • “BGB-A317”, 2 entries
  • “Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)”, 1 entry
  • “Tislelizumab (BGB-A317)”, 1 entry
  • “Subcutaneous Tislelizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.